Dr. Hill on the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

Video

Brian T. Hill, MD, PhD, discusses the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician, Taussig Cancer Institute, and assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

In October 2017, ​the FDA approved axicabtagene ciloleucel (axi-cel; Yescarta) for the treatment of adult patients with certain types of large B-cell lymphoma, including DLBCL, who have not responded to or who have relapsed after 2 or more treatments. Additionally, in May 2018, another CAR T-cell therapy product, tisagenlecleucel (Kymriah) was approved in a similar indication.  

Prior to these approval​s, therapeutic options were limited for patients who relapsed after autologous stem cell transplantor were ineligible for transplant.

However, the rate of durable remission is limited to 40% to 50% ​of patients with relapsed/refractory DLBCL. As such, there is a significant need to develop additional therapies ​in this space, Hill concludes. 

Recent Videos
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
© 2025 MJH Life Sciences

All rights reserved.